Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

A Boston-based nonprofit is among six organizations that on Monday filed a lawsuit against the U.S. Health and Human Services ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...